# A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

> **NCT07647094** · PHASE2 · RECRUITING · sponsor: **People's Hospital of Quzhou** · enrollment: 112 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Serplulimab, Nab-Paclitaxel, Carboplatin

## Key facts

- **NCT ID:** NCT07647094
- **Lead sponsor:** People's Hospital of Quzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647094, "A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07647094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*